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Background: Periventricular leukomalacia (PVL) is a type of multifactorial brain injury that causes cerebral palsy in
premature infants. To date, effective therapies for PVL have not been available. In this study, we examined whether
mesenchymal stem cells (MSCs) possess neuroprotective property in a lipopolysaccharide (LPS)-induced neonatal
rat PVL-like brain injury.
Methods: Human umbilical cord-derived MSCs (UCMSCs) were used in this study. Four-day-old rats were
intraperitoneally injected with LPS (15 mg/kg) to cause the PVL-like brain injury and were treated immediately
after the LPS-injection with UCMSCs, conditioned medium prepared from MSCs (UCMSC-CM) or interferon-gamma
(IFN-γ)-pretreated MSC (IFN-γ-UCMSC-CM). To assess systemic reaction to LPS-infusion, IFN-γ in sera was measured by
ELISA. The brain injury was evaluated by immunostaining of myelin basic protein (MBP) and caspase-3. RT-PCR was
used to quantitate pro-inflammatory cytokine levels in the brain injury, and the expression of tumor necrosis factor-
stimulated gene-6 (TSG-6) or indoleamine 2,3-dioxygenase (IDO) to evaluate anti-inflammatory or immunomodulatory
molecules in UCMSCs, respectively. A cytokine and growth factor array was employed to investigate the cytokine
secretion profiles of UCMSCs.
Results: Elevated serum IFN-γ was observed in LPS-infused rats. The expression of IL-6, tumor necrosis factor-alpha
(TNF-α), IL-1ß, and monocyte chemoattractant protein-1 (MCP-1) were increased in the brain by LPS-infusion in
comparison to saline-infused control. LPS-infusion increased caspase-3-positive cells and decreased MBP-positive area
in neonatal rat brains. A cytokine and growth factor array demonstrated that UCMSCs secreted various cytokines and
growth factors. UCMSCs significantly suppressed IL-1ß expression in the brains and reversed LPS-caused decrease in
MBP-positive area. UCMSC-CM did not reverse MBP-positive area in the injured brain, while IFN-γ-UCMSC-CM
significantly increased MBP-positive area compared to control (no treatment). IFN-γ-pretreatment increased TSG-6 and
IDO expression in UCMSCs.
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Conclusion: We demonstrated that bolus intraperitoneal infusion of LPS caused PVL-like brain injury in neonatal rats
and UCMSCs infusion ameliorated dysmyelination in LPS-induced neonatal rat brain injury. Conditioned medium
prepared from IFN-γ-pretreated UCMSCs significantly reversed the brain damage in comparison with UCMSC-CM,
suggesting that the preconditioning of UCMSCs would improve their neuroprotective effects. The mechanisms
underline the therapeutic effects of MSCs on PVL need continued investigation to develop a more effective treatment.
Keywords: Mesenchymal stem cells, Regeneration, Inflammation, Neonatal brain injuryBackground
Periventricular leukomalacia (PVL) is a serious neonatal
complication, in which periventricular white matter brain
is injured in a fetus or neonate, which leads to cerebral
palsy. Therefore, PVL exerts a critical influence over the
prognosis of a premature infant. PVL has a multifactorial
etiology that includes intrauterine infection/inflammation,
neural cell and vascular prematurity, ischemia/reperfusion,
and microglial activation. It causes dysmyelination due to
disturbances in oligodendrocyte lineage development [1].
Despite the high prevalence of the disease, no effective
therapies are available.
Mesenchymal stem cells (MSCs) are somatic tissue-
derived cells with self-renewability and the potential to
differentiate into various cell linages. Recently, therapeutic
effects of MSCs for neurological diseases, such as
hypoxic-ischemic encephalopathy, cerebral infarction,
Alzheimer’s disease, and Parkinson’s disease, have been
reported [2–6]. Several groups, including ours, have shown
that MSCs differentiate into neurofilament (NFM)-positive
neuron-like cells, glial fibrillary acidic protein (GFAP)-
positive astrocyte-like cells, and 2′,3′-cyclic-nucleotide
3′-phosphodiesterase (CNPase)-positive oligodendrocyte-
like cells [7–11]. MSCs are also known to secrete growth
factors, cytokines, and chemokines for a wide range of
activities, such as vascular endothelial growth factor re-
ceptor (VEGF) for anti-apoptosis; VEGF, and fibroblast
growth factors (FGF-2) for angiogenesis; human tumor
necrosis factor-stimulated gene-6 (TSG-6) and prosta-
glandin E2 (PGE-2) for anti-inflammation; indoleamine
2,3-dioxygenase (IDO),transforming growth factor (TGF-β),
inducible nitric oxide synthase (iNOS) for immunomodula-
tion; TGF-β, hepatocyte growth factor (HGF) anti-scarring;
stromal cell-derived factor-1 (SDF-1) for chemoattraction,
homing to injured tissues, and support of growth and dif-
ferentiation of stem and progenitor cells in lesions [12–14].
IDO plays a critical role in immunomodulation by MSCs in
its stimulation of regulatory T cells [15]. The expression
of IDO in MSCs is upregulated under hypoxic condi-
tions or with IFN-γ pretreatment [16, 17]. TSG-6 is one
of the genes activated in response to inflammatory
stimuli, such as TNF-α, IL-1, LPS, and TGF-β. Thera-
peutic activities of MSCs are known to depend in part on
TSG-6 in animal disease models, such as those of cerebralischemia, autoimmune encephalomyelitis, diabetes, and
peritoneal adhesions [18].
In addition, Chang CP et al. found that MSCs changed
their properties with culture conditions or in response
to microenvironments such as inflammation and hypoxia
[19]. Similar observation was also found that the effects of
MSCs were reinforced by crosstalk with inflammatory
stimulants and other affected cells [20].
In this study, we developed a neonatal rat with PVL-like
brain injury by intraperitoneal administration of lipopoly-
saccharide (LPS) and examined the therapeutic effect of
UCMSCs. Myelin basic protein (MBP) is a major struc-
tural component of myelin and is exclusively expressed in
myelinating oligodendrocytes in brain. We found that
LPS-infusion led to increase in the number of caspase-
3-positive cells and reduction in MBP-positive area and
that UCMSCs ameliorated LPS-induced reduction of
MBP. In contrast, UCMSC-CM did not reverse MBP-
positive area in the injured brain. We also found that
conditioned medium prepared from IFN-γ-pretreated
UCMSC (IFN-γ-UCMSC-CM) ameliorated reduction
of MBP and that various cytokines, including TSG-6 or




Postnatal day 4 (P4) Sprague-Dawley rats weighting
9–10 g were provided by Sankyo Labo Service Corpor-
ation, Inc. (Tokyo, Japan). All experimental procedures
were performed in accordance with guidelines of the Insti-
tutional Animal Care and Use Committee, and were ap-
proved by the Animal Research Committee, Graduate
School of Medical and Dental Science, Tokyo Medical and
Dental University (0140112C). Animals were maintained
in a temperature-controlled animal care facility under a
12-h light/dark cycle with a constant supply of food and
water.
Cell culture
Human umbilical cords-derived MSCs (UCMSCs) were
obtained from Promo Cell GmbH (Heidelberg, Germany)
or The Institute of Medical Science, The University of
Tokyo. Two different sources of UCMSCs were examined
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ation assay. We confirmed that both cells exhibited MSC
phenotype based on their cell surface marker expression
and their differentiation capability into osteoblasts, chon-
droblasts, and adipocytes. All experimental procedures
were approved by the Institutional Ethics Committee,
Graduate School of Medical and Dental Science, Tokyo
Medical and Dental University. The MSCs used in all
experiments were from passage 4–7. The cells were
cultured in a humidified incubator at 37 °C with 5%
CO2 in α-minimum essential medium (α-MEM) (Life
Technologies Japan, Tokyo, Japan) supplemented with
10% heat-inactivated fetal bovine serum, 1% antibiotic-
antimycotic solution (Life Technologies Japan), and
1% L-glutamine (Life Technologies Japan). The medium
was changed every 3 days.
Preparation of the rat PVL model
To generate an inflammation-related PVL-like brain injury
in rats, pups were injected with LPS (Escherichia coli,
055:B5, Sigma-Aldrich, St. Louis, MO, USA) intraperito-
neally on day 4 at a dose of 15 mg/kg in 50 μl saline
using a 32-gauge needle. The control pups received equal
amounts of saline intraperitoneally. The dose schedule
was based on a preliminary study. After this procedure,
pups were housed with dams for 48 h or 8 d, as required
for further experiments. Systemic reaction to the LPS-
injection was monitored by IFN-γ in sera. The brain in-
jury was assessed by proinflammatory chtokine level
and MBP area.
Preparation and treatment of MSC and MSC-conditioned
medium (MSC-CM)
The UCMSCs were cultured in α-MEM supplemented
with 10% fetal bovine serum to 70% confluency, when the
medium was replaced with serum-free low-glucose
DMEM (Life Technologies Japan). The UCMSCs were
cultured in serum-free medium for 48 h to collect con-
ditioned medium. Then, the conditioned medium was
concentrated 20-fold using an Amicon Ultra with a 10-kDa
cut-off (Millipore, Billerica, MA) and stored at 4 °C for the
following experiment.
We injected saline or LPS into rats on postnatal day 4.
In the LPS group, animals were randomly assigned to one
of the two groups to receive intraperitoneal injections of
UCMSCs, UCMSC-CM, or serum-free DMEM as a con-
trol medium, immediately after LPS-administration. Each
pup was administered 1 × 106 cells in 100 μl of serum-free
DMEM for the UCMSC treatment or 100 μl of UCMSC-
CM on 4 consecutive days. The concentrated conditioned
medium was prepared with the secretions from an
approximately equivalent number of UCMSCs (1 × 106
MSCs). For the pretreatment of UCMSCs by IFN-γ,
UCMSCs were treated with recombinant human IFN-γ(10 ng/ml, R&D Systems, Minneapolis, MN, USA). For
the RT-PCR analysis, total RNA was extracted from
UCMSCs 24 h after IFN-γ stimulation. The conditioned
medium was collected and concentrated for treatment of
LPS induced brain injury at 48 h after IFN-γ stimulation.
Tissue preparation
Animals were deeply anesthetized by pentobarbital sodium
and transcardially perfused with 0.1 M phosphate-buffered
saline (PBS, pH 7.4), followed by 4% paraformaldehyde.
Brains were removed from coronal sections at approxi-
mately the bregma on P12 and postfixed for 1 day in the
same fixative, followed by 7-day incubation in 70% ethanol
at 4 °C, and then dehydrated by graded alcohol concentra-
tion and embedded in paraffin. Coronal sections were cut
at 6-μm thickness using a bright rotary microtome (Leica
RM 2235 Wetzlar, Germany), and four sequential sections
were collected.
Immunohistochemical and histological analyses
To evaluate white matter injury, we investigated by im-
munohistochemistry the expression of MBP, which is a
mature oligodendrocyte marker. For the immunohisto-
chemistry, paraffin-embedded sections were deparaffinized
in xylol, rehydrated with decreasing alcohol concentra-
tions, and heat-unmasked for 15 min in 10-mM citrate
buffer (pH 6.0). To inhibit endogenous peroxidase activity,
sections were treated with 0.3% hydrogen peroxide and
then blocked for 30 min with PBS containing 2% normal
horse serum. Sections were incubated with primary
antibodies, mouse monoclonal MBP (1:500; SMI-94R,
Covance, Princeton, NJ), and caspase-3 antibody (1:1000;
Cell Signaling Technology Japan), overnight at 4 °C in a
wet chamber. After extensive washes in PBS, sections were
further incubated with biotinylated secondary antibody for
30 min at room temperature, followed by application of
peroxidase-coupled avidin-biotin complex (ABC Kit,
Vector Laboratories, Burlingame, CA). The immunoreac-
tion products were visualized with 3, 3-diaminobenzidine
(DAB, Sigma-Aldrich), then counterstained with methyl
green. All images were blinded and obtained on a light
microscope (CTR 5000B, Leica, Wetzlar, Germany). We
measured the positive area by ImageJ software (version
1.27z, National Institute of Health, Bethesda, MD, USA).
RNA extraction and real-time RT-PCR analysis
In order to investigate the mechanisms underlying
UCMSC or UCMSC-CM effects, we examined the in-
flammatory cytokine and chemokine expression levels in
P6 rat brains using real-time RT-PCR. For total RNA
isolation, the periventricular white matter tissue was
removed from gross coronal sections from approxi-
mately −1 to +1 mm bregma. The tissue was immedi-
ately submerged in RNAlater solution (Invitrogen, Carlsbad,
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was homogenized by Polytron (Central Scientific Com-
merce, Tokyo, Japan) with Isogen (Nippon Gene Co.
Tokyo, Japan).
To investigate the secretion profiles of UCMSCs influ-
enced by IFN-γ, we checked the expression of TSG-6 or
IDO in MSCs with and without stimulation by IFN-γ.
Total RNA from cell monolayers was extracted using an
RNeasy Mini Kit (Qiagen, Venlo, Netherlands) after in-
cubation for 24 h in the presence of IFN-γ.
About 1 μg of total RNA per sample was used to
synthesize double-stranded cDNA by reverse transcription
(First Strand cDNA Synthesis Kit for RT-PCR, AMV,
Roche Diagnostics, Basel, Switzerland).
Real-time amplification was performed with SYBER
GREEN I Master (Roche Diagnostics) and analyzed on
a Light Cycler System (Light Cycler 480 II, Roche
Diagnostics).
The assay was performed in three technical replicates
for each biological sample.
Results of the targeted mRNA were normalized against
the internal control, GAPDH.
Cytokine array
An analysis of cytokines in conditioned media was per-
formed using the Proteome Profiler Human Cytokine
Array Panel A (R&D Systems) according to the manu-
facturer’s instructions. A growth factor analyses was
performed using the Ray Bio C-Series Human Growth
Factor Antibody Array C1 (Ray Biotech, Norcross, GA,
USA). Colorimetric analysis using a luminescent image
analyzer (Image Quant LAS 4000 mini) was used to quan-
tify the intensity of each membrane dot, which allowed
for the assessment of growth factor content in the
UCMSC-CM. The conditioned media was used after
20-fold concentration.
ELISA
Rat serum IFN-γ (Rat IFN-γ ELISA kit; R&D Systems)
was detected with a commercially available ELISA kit
following the procedures described by the manufacturer.
Statistical analysis
All statistical analyses were performed using JMP software
(SAS Institute Inc., NC, USA). Data are presented as
the mean ± SEM. Multiple group comparisons were
performed by Dunnett’s test. A two-tailed paired t test
was used for pairwise comparisons. Statistical significance
was defined as p < 0.05.
Results
LPS-induced rat PVL-like brain injury model
We examined whether intraperitoneal administration of
LPS caused white matter degradation in neonatal rats.According to our preliminary experiments (data not shown),
the optimal dose (15 mg/kg) of LPS was used to cause
white matter degradation with less than 80% mortality
in four-day-old rats in this study.
In brain sections, immunostaining of MBP in brain
sections showed coarse-staining and a reduction in the
positive-staining area (Fig. 1a, b), and caspase-3-positive
cells were increased in the LPS group, (Fig. 1c, d), indi-
cating that the administration of LPS successfully caused
white matter brain injury in neonatal rats. In order to
examine the systemic reaction of the rats to LPS-infusion,
we also measured the serum level of IFN-γ by ELISA and
found that IFN-γ was significantly increased in the LPS
group (Fig. 1e). In the brain, the expression of IL-6, tumor
necrosis factor-alpha (TNF-α), IL-1ß, and monocyte chemo-
attractant protein-1 (MCP-1) were increased by LPS-
infusion in comparison to saline-infused control (Fig. 1f).The effect of UCMSCs on LPS-induced brain injury
First, we confirmed that UCMSCs were positive for CD44,
CD73, CD90, and CD105, and negative for CD11b, CD31,
CD34, CD45, and HLA-DR by flow cytometric analyses.
Differentiation of UCMSCs into osteoblasts, adipocytes,
or chondrocytes in the induction medium was also con-
firmed (data not shown). Next, we examined a cytokine
and growth factor array and confirmed that UCMSCs se-
creted various cytokines and growth factors such as MCP-
1, MIF, IGFBP-6, and PDGF (Fig. 2a).
In order to investigate whether UCMSCs affected
LPS-induced white matter brain injury in neonatal
rats, UCMSCs were administrated intraperitoneally
immediately after the LPS injection. We found that
the administration of UCMSCs significantly reversed
the MBP-positive area on P12 rats in the LPS-MSC
group in comparison with that in the LPS control
group, implying that UCMSCs-infusion significantly
improved myelination (Fig. 2b, c). To investigate the
effect of UCMSCs on inflammatory cytokine expression
in the lesion, the mRNA expression of inflammatory
cytokines in rat brains were analyzed by real-time
RT-PCR 48 h after UCMSC-infusion. The administration
of UCMSCs tended to decrease the proinflammatory
cytokine levels. Among them, the effect of UCMSCs on
IL-1β suppression was statistically significant (Fig. 2d).The effect of UCMSC-CM on LPS-induced brain injury
We then examined whether UCMSC-CM could also sup-
pressed LPS-induced white matter brain injury. UCMSC-
CM was administrated four consecutive days after the
LPS-injection. Although a trend towards suppressed
expression in the inflammatory cytokines levels were
observed in the brain (Fig. 3c), UCMSC-CM did not
reverse the MBP-positive area on P12 (Fig. 3a, b).
Fig. 1 LPS-induced white matter brain injury. a The area of white matter was evaluated by MBP staining on postnatal day 12. Representative images
from each group. From the left, the saline group and LPS group are shown. Scale bar: 100 μm. b Quantitative analysis of the MBP-positive areas in each
group. Four sections were evaluated per pup. N = 21 and 18 in each group, values indicate means ± S.E. *, p < 0.05; assessed by t test. c The areas of
white matter was evaluated by caspase-3 staining on postnatal day 12. Representative images of each group. From the left, the saline group and LPS
group are shown. Scale bar: 100 μm. d Quantitative analysis of the caspase-3-positive area in each group. Four sections were evaluated per pup. N = 8
per group, values indicate means ± S.E. *; p < 0.05; assessed by t test. e IFN-γ levels in sera were assayed by ELISA at 6 h after LPS injection and
compared with levels in the saline group. f The mRNA levels of pro-inflammatory cytokines and chemokines in brain tissues at 48 h after LPS
treatment were determined by quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR). Relative mRNA expression
levels of IL-6, TNF-α, IL-1β, and MCP-1 compared with levels in the saline group. N = 5, values indicate means ± S.E. *, p < 0.05; assessed by t test
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white matter brain injury
We next examined discrepancy in the neuroprotective
effect between UCMSCs and UCMSC-CM in this model.
Previously, it has been reported that MSCs exposed to
inflammatory stimuli exhibited anti-inflammatory effects
[21]. Folkerth et al. have reported that macrophage-
produced IFN-γ plays a role in PVL [22]. We found thatthe serum level of IFN-γ was significantly increased in
the LPS group (Fig. 1e). We examined whether IFN-γ-
preconditioning of UCMSCs could improve the effect
of UCMSC-CM in LPS-induced dysmyelination. IFN-γ-
UCMSC-CM was administrated four consecutive days
immediately after the LPS-injection. In contrast to
UCMSC-CM, IFN-γ-UCMSC-CM effectively reversed
the MBP area on P12 (Fig. 4a, b), suggesting that
Fig. 2 The effect of UCMSCs on LPS-induced brain injury. a Graphs showed the relative intensity ratios of growth factors found in the conditioned
media to that of the provided positive control. b The area of white matter was evaluated by MBP staining after MSC treatment on postnatal day
12. Representative images from each group. From the left, the saline group, LPS-control group and LPS + MSC group are shown. Scale bar: 100 μ.
c Quantitative analysis of the MBP-positive areas in each group. Four sections were evaluated per pup. N = 8 in each group, values indicate
means ± S.E. *, p < 0.05; assessed by t test. d The mRNA levels of pro-inflammatory cytokines and chemokines in brain tissues at 48 h after MSC
treatment were determined by qRT-PCR. Relative mRNA expression levels of IL-6, TNF-α, IL-1β, and MCP-1 compared with levels in the saline
group. N = 5, values indicate means ± S.E. *, p < 0.05; assessed by t test
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neuroprotecitive effects of UCMSCs. Our preliminary
experiments showed that no big differences in cytokine
secretion profile between UCMSC-CM and IFN-γ-
UCMSC-CM. We then investigated whether the expression
of TSG-6, one of the most important anti-inflammatory
molecules in MSCs was influenced by IFN-γ-pretreatment.
Real-time RT-PCR analysis showed that the expression of
TSG-6 markedly increased when UCMSCs were pre-
treated by IFN-γ for 24 h (Fig. 4c). Moreover, IDO
expression in UXMSCs was also increased by IFN-γ-
pretreatment (Fig. 4c).
Discussion
The purpose of this study was to examine whether
UCMSCs have a therapeutic effect on an LPS-inducedrat PVL model. We generated the rat PVL-like brain in-
jury model by intraperitoneal injection of high dose-LPS
on P4, when oligodendrocyte progenitor cells proliferate
in the periventricular region of the brain. Our results
showed a decrease in MBP and increase of caspase-3 positive
cells in this region and upregulation of pro-inflammatory cy-
tokines after LPS injection, suggesting the abrogation of
myelination because of brain inflammation. Moreover,
intraperitoneally administrated MSCs abated dysmyelina-
tion in this model and suppressed LPS-induced IL-1β
levels in the brain tissues. Previous reports have shown
that MSCs improved hypoxia/ischemia-induced brain in-
jury [23, 24]. However, the mechanisms that underlie the
therapeutic effects of MSCs remain elusive. Our results
suggest that the therapeutic effects of MSCs can be attrib-
uted in part to a reduction in local inflammation.
Fig. 3 The effect of UCMSC-CM on LPS-induced brain injury. a The area of white matter was evaluated by MBP staining after MSC treatment on
postnatal day 12. Representative images from each group. From the left, the saline group, LPS-control group and LPS + MSC group are shown.
Scale bar: 100 μm. b Quantitative analysis of the MBP-positive areas in each group. Four sections were evaluated per pup. N = 8 in each group,
values indicate means ± S.E. *, p < 0.05; assessed by t test. c The mRNA levels of pro-inflammatory cytokines and chemokines in brain tissues at
48 h after MSC-CM treatment were determined by qRT-PCR. Relative mRNA expression levels of IL-6, TNF-α, IL-1β, and MCP-1 compared with
levels in the saline group. N = 5 , values indicate means ± S.E. *, p < 0.05; assessed by t test
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livered MSCs appeared to reach the inflamed or dam-
aged tissues, suggesting that the therapeutic action of
MSCs might be related to their trophic mechanisms rather
than to their ability to reach damaged tissues [25, 26]. We
then examined whether factors secreted from MSCs could
also improve LPS-induced brain injury. Contrary to our
expectations, our results showed that MSC-CM did not
suppress the MBPs degradation significantly. Intraperi-
toneally injected MSCs were recently reported to form
aggregates in the peritoneum, where they produced im-
munoregulatory or anti-inflammatory molecules [27, 28].
In a preliminary experiment, when MSCs were intraperi-
toneally administrated after LPS injection, we observed
that the luciferase labeled MSCs remained in intraperito-
neal region during 14 days without migration to the re-
gion of brain injury. Whereas, in this study, MSC-CM
prepared from the same number of MSCs used for the cell
administration study did not show therapeutic effects.
Previously, Duijvestein et al. reported that MSCs ex-
posed to inflammatory stimuli such as IFN-γ exhibit
anti-inflammatory effects [21]. We assumed that the dif-
ference between the effects of MSCs and MSC-CM on
myelination was due to pre-exposure of the MSCs to
IFN-γ. We demonstrated that IFN-γ-MSC-CM improved
MBP levels compared to the control, suggesting that
IFN-γ-pretreatment could augment the therapeutic effects
of MSCs. Our preliminary experiments showed that
IFN-γ levels in the conditioned medium with or with-
out IFN-γ-pretreat were not detectable, suggesting that
the augmented therapeutic effects of MSCs were notattributed to carryover effects of IFN-γ. Intriguingly,
we found that the expression of the anti-inflammatory
factor TSG-6 and IDO was increased by IFN-γ stimu-
lation. These results suggest that MSCs can produce a
variety of anti-inflammatory factors following IFN-γ
stimulation.
Recent reports have shown that the paracrine potential
of MSCs can be enhanced by various pretreatments.
Chen et al. reported that bone marrow derived MSC-CM,
which was preactivated under radiation-induced inflam-
matory conditions, showed dramatic improvements in
damaged intestines and in survival of irradiated rats [29].
Moreover, preactivation of MSCs with TNF-α, IL-1β, and
nitric oxide enhanced its paracrine effects on radiation-
induced intestinal injury. Another report suggested that
the immunosuppressive properties of MSCs were aug-
mented by IFN-γ-pretreatment in vitro [30].
We demonstrated that MSCs improved LPS-induced
brain injury and that IL-1β was significantly suppressed
by MSC-treatment (Fig. 2d). However, it seems to be in-
sufficient to explain the differences in neuroprotective
effects between MSCs and MSC-CM since IL-1β tended
to be suppressed after MSC-CM-treatment (Fig. 3c). It has
been reported that therapeutic effects of MSCs were attrib-
uted to anti-inflammation, anti-apoptosis, anti-oxidization,
angiogenesis, regulation of microglia activation, activation
of oligodendrocyte differentiation. Further experiments are
required to elucidate the underlying mechanism. Moreover,
it is also interesting to employ behavior test to ask whether
MSCs or IFN-γ-MSC-CM could improve cerebral palsy in
our model.
Fig. 4 The effect of preconditioning of UCMSCs on the LPS-induced white matter brain injury. a The areas of white matter was evaluated by MBP
staining on postnatal day 12. Representative images of each group. From the left, the saline group, LPS+ control group, LPS + MSC-CM group,
and LPS + IFN-γ-MSC-CM group are shown. Scale bar: 100 μm. b Quantitative analysis of the MBP-positive area in each group. Four sections were
evaluated per pup. N = 7 or 8 per group, values indicate means ± S.E. *; p < 0.05; assessed by Dunnett’s test. c Expression levels of TSG-6 and IDO
in MSC stimulated with IFN-γ using quantitative RT-PCR. *, p < 0.05; assessed by t test
Morioka et al. Inflammation and Regeneration  (2017) 37:1 Page 8 of 10Conclusions
In conclusion, we firstly demonstrated that MSCs have
therapeutic effects on LPS-induced PVL-like brain injury
and these effects could be augmented under proper stim-
uli. The mechanisms underline the therapeutic effects of
MSCs on PVL need continued investigation to develop
more effective treatment.Abbreviations
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